Physician profile
Madelyn B King
NPI 1861420978
$8,061.91
in general payments reported to CMS, 2019-2025
30 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,999 · 2022: $1,531 · 2023: $1,771 · 2024: $1,452 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,532.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,047.41 | 2021-2025 | |
| Boston Scientific Corporation | $981.22 | 2021-2025 | Lux-Dx Insertable Cardiac Monitor, Varithena Administration Pack, Ranger |
| Medtronic, INC. | $848.01 | 2021-2025 | Onyx Frontier, Venaseal, Symplicity G3 |
| Merck Sharp & Dohme LLC | $704.31 | 2021-2025 | Verquvo, Capvaxive |
| Amgen INC. | $605.49 | 2021-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $580.22 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $569.18 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $557.14 | 2021-2025 | Wainua, Farxiga |
| Abiomed | $422.94 | 2021-2025 | Impella |
| Pfizer INC. | $223.00 | 2022-2025 | |
| Terumo Medical Corporation | $222.17 | 2021-2024 | Navicross, Glidewire, Glidesheath Slender |
| E.R. Squibb & Sons, L.L.C. | $193.84 | 2022-2025 | Camzyos, Eliquis |
| Esperion Therapeutics, INC. | $161.34 | 2021-2025 | Nexletol |
| Lexicon Pharmaceuticals, INC. | $156.42 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.64 | 2021-2023 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $111.46 | 2023-2025 | Auryon Laser System 100-120 Vac |
| Madrigal Pharmaceuticals | $100.64 | 2025 | Rezdiffra |
| Abbott Laboratories | $96.38 | 2021-2025 | Cardiomems |
| Bridgebio Pharma, INC. | $66.96 | 2025 | Attruby |
| Chiesi USA, INC. | $47.41 | 2021 | |
| Preventice Services, LLC | $41.32 | 2021 | |
| Scpharmaceuticals INC. | $35.89 | 2024 | |
| Ge Healthcare | $32.82 | 2021 | |
| Teleflex LLC | $27.84 | 2025 | Supercross |
| Bard Peripheral Vascular, INC. | $23.51 | 2024 | Rotarexs 6 F X 135 Cm |
| Takeda Pharmaceuticals U.S.A., INC. | $18.21 | 2025 | Entyvio |
| Cardiva Medical, INC. | $15.45 | 2022 | |
| Amarin Pharma, INC. | $13.01 | 2021 | |
| W. L. Gore & Associates, INC. | $12.43 | 2021 | |
| Itamar Medical INC | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madelyn King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.